That other messenger RNA biotech unicorn is looking to jump into Wall Street with an IPO that may seek a record $800 million and a valuation of some $4 billion.
Bankers are buzzing that Bank of America and JP Morgan have already been tapped for the IPO on behalf of BioNTech, a German biotech that has attracted considerable attention for its role as a leader in the mRNA field, according to a report in Reuters.
Something is bound to be going on here. Reuters’ report comes a few weeks after Bloomberg published a piece on the prospective IPO for BioNTech, citing a possible valuation of $5 billion.
Moderna blazed the IPO $MRNA path for mRNA a little more than 3 months ago, raising $604 million in a historic offering that quickly soured as its stock blew south. But that was just temporary. The stock later climbed back up and now sits at $19.75 with a $6.5 billion market cap.
Early this year Sanofi doubled down on its alliance with the biotech, fronting an expanded pact with $91 million in cash for immunotherapies designed to go after solid tumors. Earlier Pfizer lined up a sizable deal to develop an mRNA flu vaccine, offering cash for an upfront and equity. And a little more than a year ago BioNTech came up with a $270 million round, bringing its total raise at the time to close to $1 billion.
The initial seed money was offered by the billionaire Strüngmann brothers, who are the majority shareholders.
The IPO window remains open for biotechs, but after a big string of new offerings in 2018, the general consensus is that there will be a decline in the number of companies making the leap onto the public stage.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,900+ biopharma pros who read Endpoints News by email every day.Free Subscription